Voices
Daisuke Kotani
Daisuke Kotani/X

Daisuke Kotani Highlights MONSTAR-3 Study on FGFR2-IIIc Isoform and Its Role in G/GEA Cancer

Daisuke Kotani, GI Medical oncologist, Chief physician at Department of Gastrointestinal Oncology at National Cancer Center Hospital East, Japan, shared a post on X:

“Our colleagues Dr. Hashimoto and MONSTAR-3 team just published in ESMO Open!

FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in G/GEA cancer.”

MONSTAR-3

Title: FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer

Authors: T. Hashimoto, N. Iida, S. Kadowaki, A. Makiyama, N. Machida, N. Takahashi, S. Boku, T. Kudo, E. Oki, K. Ohtsubo, T. Kawakami, N. Okano, Y. Komatsu, S. Yuki, N. Sakamoto, T. Kuwata, R. Yamashita, M. Amisaki, T. Shibuki, M. Imai, T. Fujisawa, Y. Nakamura, H. Bando, K. Shitara, T. Yoshino

Read Full Article.

Daisuke Kotani Highlights MONSTAR-3 Study on FGFR2-IIIc Isoform and Its Role in G/GEA Cancer

More posts about FGFR2 on OncoDaily.

A. Makiyama cancer Daisuke Kotani E. Oki FGFR2 H. Bando K. Ohtsubo K. Shitara M. Amisaki M. Imai N. Iida N. Machida N. Okano N. Sakamoto N. Takahashi OncoDaily Oncology R. Yamashita S. Boku S. Kadowaki S. Yuki T. Fujisawa T. Hashimoto T. Kawakami T. Kudo T. Kuwata T. Shibuki T. Yoshino Y. Komatsu Y. Nakamura